A Phase 2 interventional study of NS-089/NCNP-02 in Duchenne Muscular Dystrophy, Exon 44 and DMD, sponsored by NS Pharma, Inc.. Active, not recruiting at 29 sites in 7 countries. Open to male participants aged 4 Years to 14 Years. Per ClinicalTrials.gov, last updated 2026-09-15.
Sponsored by NS Pharma, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Muscular Dystrophy, Duchenne by NS Pharma, Inc. — 1 open to participants now, 5 under way, 1 of them phase 3. Muscular Dystrophy, Duchenne · NS Pharma, Inc..
Among the 10 studies in Muscular Dystrophy, Duchenne by NS Pharma, Inc., this one is one of 2 that started in 2024, is one of 5 in phase 2, and was the 8th registered.
482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →1 of the 10 studies in Muscular Dystrophy, Duchenne by NS Pharma, Inc. is open now, in 7 countries. Recruiting first, the newest first:
NS Pharma, Inc. · Sites in United States, Australia, Canada and 4 more countries
Men only
By country, each count listing its studies:
Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.
This study: 4 Years to 14 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 2 · Phase 4 1
First in 2016; this study’s year is marked. 2 started in 2024.
This study's planned enrollment of 20 is below the median of 25 across 333 interventional studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 20 across the 9 interventional studies. Of the 4 that completed or were terminated, 4 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
NS Pharma, Inc. is the lead sponsor of 16 studies on the registry; 3 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
1 of the studies in Muscular Dystrophy, Duchenne by NS Pharma, Inc. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05996003NS Pharma, Inc.NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD) | 2027-02-26 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Muscular Dystrophy, Duchenne by NS Pharma, Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, open-label, multi-center, 2-part study of NS-089/NCNP-02 administered by weekly IV infusion to ambulant boys aged ≥4 to \<15 years with DMD due to mutations amenable to exon 44 skipping. Participants will receive a selected dose of NS-089/NCNP-02 administered once weekly.
The study consists of 2 parts: Part 1 and Part 2. Six participants (Cohort 1) will participate in both Part 1 and Part 2, and 14 participants (Cohort 2) will be added for Part 2.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Experimental: NS-089/NCNP-02 NS-089/NCNP-02 solution for infusion (Cohort 1) NS-089/NCNP-02 solution for infusion (Cohort 2)
Drug: NS-089/NCNP-02
Drug page: BrogidirsenStudies of BrogidirsenBrogidirsen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Cohort 1: Part 1 Dose Level 1-3: a 4-week Treatment Phase at each treatment dose level Part 2 Single Dose Level: a 24-week Treatment Phase at the MTD of Part 1 Cohort 2: Part 2 Single Dose Level: a 24-week Treatment Phase at the MTD of Part 1
Also known as: Brogidirsen
Adverse Event and Adverse Drug Reaction
Time frame: through study completion, up to follow-up phone call for Part 2
Plasma pharmacokinetic (PK) parameters
Time frame: Day1, Week4 for each dose for Part 1, Day1 and Week24 for Part 2] Maximum plasma concentration (Cmax) of NS-089/NCNP-02
Plasma pharmacokinetic (PK) parameters
Time frame: Day1, Week4 for each dose for Part 1, Day1 and Week24 for Part 2] Time of the maximum plasma concentration (Tmax) of NS-089/NCNP-02
Plasma pharmacokinetic (PK) parameters
Time frame: Day1, Week4 for each dose for Part 1, Day1 and Week24 for Part 2] Terminal half-life (T1/2) of NS-089/NCNP-02
Plasma pharmacokinetic (PK) parameters
Time frame: Day1, Week4 for each dose for Part 1, Day1 and Week24 for Part 2] Area under the concentration-time curve from time 0 to the last time point (AUC0-t) of NS-089/NCNP-02
Plasma pharmacokinetic (PK) parameters
Time frame: Day1, Week4 for each dose for Part 1, Day1 and Week24 for Part 2] Area under the concentration-time curve from time 0 to infinity (AUC0-∞) of NS-089/NCNP-02
Plasma pharmacokinetic (PK) parameters
Time frame: Day1, Week4 for each dose for Part 1, Day1 and Week24 for Part 2] Total body clearance (CLtot) of NS-089/NCNP-02
Plasma pharmacokinetic (PK) parameters
Time frame: Day1, Week4 for each dose for Part 1, Day1 and Week24 for Part 2] The volume in the terminal state (Vz) of NS-089/NCNP-02
Urine pharmacokinetic parameters
Time frame: Day1, Week4 for each dose for Part 1, Day1 and Week24 for Part 2] Urinary excretion of NS-089/NCNP-02
Change from baseline in skeletal muscle dystrophin protein by immunoblot (Western blot).
Time frame: Baseline, Week25
Change from baseline in skeletal muscle dystrophin protein by mass spectrometry.
Time frame: Baseline, Week25
Change from baseline in skeletal muscle dystrophin protein levels by immunofluorescence staining.
Time frame: Baseline, Week25
Change from baseline in percentage of exon 44-skipped mRNA of skeletal muscle dystrophin
Time frame: Baseline, Week25
North Star Ambulatory Assessment (NSAA) score
The NSAA is a functional scale devised for use in ambulant children with Duchenne muscular dystrophy (DMD). It consists of 17 activities graded 0 (unable to perform), 1 (performs with modifications), 2 (normal movement). It assesses abilities necessary to remain ambulant that have been found to progressively deteriorate in untreated DMD patients, as well as in other muscular dystrophies such as Becker Muscular Dystrophy. NSAA Total Score ranges from 0 to 34, with a score of 34 implying normal function.
Time frame: Baseline, Week13, Week25
Time to Run/Walk 10 Meters (TTRW)
Time frame: Baseline, Week13, Week25
Time to Stand (TTSTAND)
Time frame: Baseline, Week13, Week25
Total distance of 6 Minute Walk Test (6MWT)
Time frame: Baseline, Week13, Week25
Time to Climb 4 Stairs (TTCLIMB)
Time frame: Baseline, Week13, Week25
Muscle strength measured by Quantitative Muscle Testing (QMT)
Time frame: Baseline, Week13, Week25
Grip and pinch strength
Time frame: Baseline, Week13, Week25
Performance of Upper Limb (PUL) 2.0. score
The PUL 2.0 provides both a total score and sub-scores for the 3 domains (shoulder, middle, and distal) that in DMD are progressively involved with a proximal to distal gradient. The PUL includes 22 items with an entry item to define the starting functional level. The 22 items are subdivided into the high-level shoulder dimension (6 items), middle level elbow dimension (9 items), and distal wrist and hand dimension (7 items). For weaker patients, a low score on the entry item (0-2) means high level items do not need to be performed. Scoring options vary across the scale between 0-1 and 0-2 according to performance. Each dimension can be scored separately with a maximum score of 12 for the high-level shoulder dimension, 17 for the middle level elbow dimension, and 13 for the distal wrist and hand dimension. A total score can be achieved by adding the 3 level scores (maximum total score of 42).
Time frame: Baseline, Week13, Week25
Started Feb 2024 (actual). Primary completion is estimated for Feb 2027, 36 months after the start.
Of 40 industry-sponsored phase 2 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 42. This study's planned 36 months is above that.
Counting every sponsor, half of 47 studies reached it within 31 months; a quarter within 20 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brogidirsen
Muscular Dystrophy, Duchenne →
NS Pharma, Inc.